LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome

The purpose of this study is to evaluate whether levetiracetam can prevent epileptic seizures in patients with Alzheimer's disease associated with Down syndrome. It will also analyze whether it can delay the neurodegeneration associated with this disease. Patients will be randomly assigned to one of two groups: one group will receive the active drug (levetiracetam), and the other will receive a placebo. Both groups will receive the treatment for 96 weeks. Each patient will participate for a total of 2 years and 5 months.

NCT Number	NCT07234695
Lead Sponsor	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau Collaborators: Fundación de Investigación Biomédica - Hospital Universitario de La Princesa, Hospital Universitario Marqués de Valdecilla, Fundación CITA Alzheimer, University Hospital Virgen de las Nieves
Conditions	Down Syndrome, Down Syndrome (DS), Down Syndrome (Trisomy 21), Alzheimer Dementia, Alzheimer Dementia (AD), Alzheimer Disease, Alzheimer Disease (AD), Alzheimer Blood Biomarkers +2 more
Enrollment	120 participants
Start Date	2025-12-22
Primary Completion	2027-12 (estimated)
Study Completion	2028-07 (estimated)
Updated on ClinicalTrials.gov	2026-01-12